^
Association details:
Biomarker:MYC rearrangement + BCL6 rearrangement
Cancer:Diffuse Large B Cell Lymphoma
Regimen:EPOCH-R (cyclophosphamide + doxorubicin hydrochloride + etoposide IV + + Rituxan (rituximab) + vincristine)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

2131 Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number

Published date:
11/04/2020
Excerpt:
These results confirm the favourable outcome of patients with MYC and BCL-2 and/or BCL-6 rearrangements or gene ICN with R-DA-EPOCH therapy.
Secondary therapy:
EPOCH